Cure8 research brief
Rheumatological EIMs (notably joint inflammation) are frequent in IBD and affect quality of life; inconsistent definitions and lack of validated PROs make it harder for patients and clinicians to understand and compare how treatments affect these outcomes.
Clinicians who manage IBD patients, clinical trialists designing IBD studies, researchers studying EIMs, and patients with IBD who experience joint symptoms.
The authors reviewed studies and trials that reported on IBD-associated rheumatological EIMs and found wide heterogeneity in diagnostic criteria and outcome measures.
There are no patient-reported outcome instruments specifically developed or validated for rheumatological EIMs in IBD, and phase 3 IBD trials often lack structured, harmonized assessment of these manifestations.
What this means practically: Better, standardized definitions and EIM-specific PROs could improve how clinicians track joint-related EIMs and how trials measure rheumatological outcomes. For now, variability in assessment may affect trial reporting and the interpretation of treatment effects on rheumatological EIMs.
This article is a narrative literature review (abstract provided). It summarizes methodological variability and calls for standardized definitions and development of PROs; it does not report new trial results or novel biomarkers. The review found heterogeneity across observational studies and randomized trials but did not validate a specific new instrument.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Respiratory diseases (COPD, asthma, bronchiectasis) and IBD appear to occur together more often than expected. If you have IBD, especially Crohn’s, you may be at higher risk for some obstructive lung diseases, and people...
PSC is rare in the general population but substantially more common in people with IBD, particularly ulcerative colitis, and it raises long-term hepatobiliary risks including cholangiocarcinoma—so knowing how often PSC...
This meta-analysis suggests people with IBD—especially those with Crohn’s disease—have a modestly increased risk of stroke. That makes cardiovascular risk assessment and prevention potentially more important for people...
